Originally approved by the U.S. Food and Drug Administration (FDA) for its antihistamine properties, clemastine can also promote white matter integrity and has shown promise in the treatment of demyelinating diseases such as multiple sclerosis. Here, we conducted an in-depth analysis of the feasibility, safety, and neuroprotective efficacy of clemastine administration in near-term lambs ( = 25, 141-143 days) following a global ischemic insult induced via an umbilical cord occlusion (UCO) model. Lambs were randomly assigned to receive clemastine or placebo postnatally, and outcomes were assessed over a six-day period. Clemastine administration was well tolerated. While treated lambs demonstrated improvements in inflammatory scores, their neurodevelopmental outcomes were unchanged.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670092PMC
http://dx.doi.org/10.3390/children10111728DOI Listing

Publication Analysis

Top Keywords

clemastine administration
8
clemastine
5
clemastine neurophysiological
4
neurophysiological outcomes
4
outcomes ovine
4
ovine model
4
model neonatal
4
neonatal hypoxic-ischemic
4
hypoxic-ischemic encephalopathy
4
encephalopathy originally
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!